1 research outputs found
Realâworld assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVIDâ19 disease) in patients with Multiple Myeloma receiving systemic antiâcancer therapy.
Infection with the novel coronavirus SARSâCoVâ2 virus resulting in an acute respiratory disease (COVIDâ19 disease) is the cause of the current pneumonia pandemic, with a rapid rise in cases being reported in the European Union and UK (1, 2). The UK index case was identified on the 31st of January, 2020 and given the rapid spread and high mortality rate of COVIDâ19, it is imperative to define the impact on patients with coâexisting medical conditions(3)